Table of Contents

State/Territory Name: Oregon

State Plan Amendment (SPA)#: 23-0024

This file contains the following documents in the order listed

- 1) Approval Letter
- 2) CMS 179 Form
- 3) Approved SPA Pages

DEPARTMENT OF HEALTH & HUMAN SERVICES Centers for Medicare & Medicaid Services 7500 Security Boulevard, Mail Stop S2-14-26 Baltimore, Maryland 21244-1850



<u>Center for Medicaid and CHIP Services</u> Medicaid Benefits and Health Programs Group

September 12, 2023

Dana Hittle, Medicaid Director Oregon Health Authority 500 Summer Street Northeast, E-15 Salem, OR 97301-1079

Dear Dana Hittle,

The CMS Division of Pharmacy team has reviewed Oregon's State Plan Amendment (SPA) 23-0024 received in the CMS Medicaid & CHIP Operations Group on August 2, 2023. This SPA has been submitted to allow the state to enter outcome-based agreements with manufactures on a voluntary basis.

Based on the information provided and consistent with the regulations at 42 CFR 430.20, we are pleased to inform you that OR-23-0024 is approved with an effective date of July 1, 2023. We are attaching a copy of the signed CMS-179 form, as well as the pages approved for incorporation into Oregon's state plan.

If you have any questions regarding this request, please contact Michael Forman at 410-786-2666 or michael.forman@cms.hhs.gov.

Sincerely,



Cynthia R. Denemark, R.Ph. Director Division of Pharmacy

Cc: Jesse Anderson, Oregon Health Authority Brandon Wells, Oregon Health Authority Deborah Weston, Oregon Health Authority Nikki Lemmon, CMS Division of Program Operations

CENTERS FOR MEDICARE & MEDICAID SERVICES	OMB NO. 0938-0	
	1. TRANSMITTAL NUMBER 2. STATE	
TRANSMITTAL AND NOTICE OF APPROVAL OF	2 3 <u>0 0 2 4</u> OR	
STATE PLAN MATERIAL FOR: CENTERS FOR MEDICARE & MEDICAID SERVICES	3. PROGRAM IDENTIFICATION: TITLE OF THE SOCIAL	
FOR: CENTERS FOR MEDICARE & MEDICAID SERVICES		
TO: CENTER DIRECTOR CENTERS FOR MEDICAID & CHIP SERVICES	4. PROPOSED EFFECTIVE DATE	
DEPARTMENT OF HEALTH AND HUMAN SERVICES	7/1/23	
5. FEDERAL STATUTE/REGULATION CITATION	6. FEDERAL BUDGET IMPACT (Amounts in WHOLE dollars)	
1902(a)(30)(A), 1927 of the ACT and 42 CFR 440.120	a FFY 2024 \$ 0 b FFY 2025 \$ 0	
7 DAGE NUMBER OF THE PLAN OF OTION OF ATTACHMENT		
7. PAGE NUMBER OF THE PLAN SECTION OR ATTACHMENT	8. PAGE NUMBER OF THE SUPERSEDED PLAN SECTION OR ATTACHMENT (If Applicable)	
Attachment 3.1-A, Page 5-b, 5-c	Attachment 3.1-A, Page 5-b	
9. SUBJECT OF AMENDMENT		
This transmittal is being submitted to allow the state to enter value	e-based contracts with manufactures on a voluntary basis.	
	,,,	
10. GOVERNOR'S REVIEW (Check One)		
GOVERNOR'S OFFICE REPORTED NO COMMENT	OTHER, AS SPECIFIED:	
COMMENTS OF GOVERNOR'S OFFICE ENCLOSED		
O NO REPLY RECEIVED WITHIN 45 DAYS OF SUBMITTAL		
11. SIGNATURE OF STATE AGENCY OFFICIAL	15. RETURN TO	
	Oregon Health Authority	
12. TYPED NAME	Medical Assistance Programs	
Dana Hittle	500 Summer Street NE E-65	
13. TITLE	Salem, OR 97301	
Medicaid Director	ATTN: Jesse Anderson, State Plan Manager	
14. DATE SUBMITTED		
8/2/23 FOR CMS 0		
16. DATE RECEIVED	17. DATE APPROVED	
August 2, 2023	September 12, 2023	
PLAN APPROVED - O		
18. EFFECTIVE DATE OF APPROVED MATERIAL	19. SIGNATURE OF APPROVIN	
July 1, 2023		
20. TYPED NAME OF APPROVING OFFICIAL	21. TITLE OF APPROVING OFFICIAL	
Cynthia R. Denemark	Director, Division of Pharmacy	
22. REMARKS		

Transmittal #23-0024 Attachment 3.1-A Page 5-b

STATE PLAN UNDER TITLE XIX OF THE SOCIAL SECURITY ACT State/Territory: <u>OREGON</u>

AMOUNT, DURATION, AND SCOPE OF MEDICAL AND REMEDIAL CARE AND SERVICES PROVIDED TO THE CATEGORICALLY NEEDY

LIMITATIONS ON SERVICES (Cont.)

12.a. Prescribed Drugs

Supplemental Rebate Agreement:

The state will be negotiating supplemental rebates in addition to the federal rebates provided for in Title XIX under the national rebate program. Supplemental rebate agreements between the state and a pharmaceutical manufacturer will be separate from the federal rebates received under the national rebate program.

CMS has authorized Oregon to enter into "The Sovereign States Drug Consortium (SSDC)" Medicaid Multi-State purchasing pool in relation to supplemental rebates.

The Centers for Medicare and Medicaid Services (CMS) has authorized a rebate agreement between the state and a drug manufacturer that provides supplemental rebates for drugs provided to the Oregon Medicaid program as follows:

- A supplemental rebate agreement submitted to CMS on 6/19/2003 and entitled, "State of Oregon, Supplemental Rebate Agreement" has been authorized by CMS.
- A supplemental rebate agreement submitted to CMS on 7/15/09, amended the 6/19/03 version of the "State of Oregon, Supplemental Rebate Agreement" under Transmittal 03-02, has been authorized by CMS.
- A supplemental rebate agreement submitted to CMS on 8/2/10 amended the 7/15/09 version of the "State of Oregon, Supplemental Rebate Agreement" authorized under Transmittal 09-05, has been authorized by CMS.
- CMS has authorized the state of Oregon to enter into outcome-based agreements with pharmaceutical manufacturers, on a voluntary basis, for drugs provided to Medicaid beneficiaries using the outcome-based supplemental rebate agreement beginning July 1, 2023.

Transmittal #23-0024 Attachment 3.1-A Page 5-c

STATE PLAN UNDER TITLE XIX OF THE SOCIAL SECURITY ACT State/Territory: <u>OREGON</u>

AMOUNT, DURATION, AND SCOPE OF MEDICAL AND REMEDIAL CARE AND SERVICES PROVIDED TO THE CATEGORICALLY NEEDY

LIMITATIONS ON SERVICES (Cont.)

12.a. Prescribed Drugs (Cont)

Savings recognized from value-based purchasing and supplemental rebate agreements received by the State in excess of those required under the national drug rebate agreement will be shared with the Federal government on the same percentage basis as applied under the national rebate agreement.

All drugs covered by the program, irrespective of a prior authorization agreement, will comply with the provisions of the national drug rebate agreement.

The state will maintain the flexibility to negotiate supplemental rebate payments by manufacturers for Medicaid Managed Care Organization (MCO) utilization of products on the PDL regardless of whether the products are on the Medicaid MCO formularies (Version 1 of Attachment A, Transmittal 10-13).

TN No.	23-0024	
Superse	edes TN No.	NEW

Approval Date: 9/12/23 Effective Date: 7/1/23